An unusual coalition of medullary nephrocalcinosis with a novel genotypic variant of Alport syndrome type-1
DOI:
https://doi.org/10.18203/2320-6012.ijrms20233726Keywords:
Alport syndrome, Haematuria, Proteinuria, NephrocalcinosisAbstract
Alport’s syndrome is a type of inherited disorder of the basement membrane characterized by a spectrum of phenotypes ranging from progressive renal injury to varied extrarenal manifestations comprising auditory and ocular abnormalities. Here in, we present a 3-year-old child born out of nonconsanguineous marriage who presented with fever, intermittent microscopic haematuria, and recurrent gross haematuria, proteinuria with normal auditory brainstem response and ocular slit lamp examination findings. Renal biopsy yielded normal light microscopy and immunofluorescence study whereas minimal changes in the glomerular basement membrane (GBM) collagen were detected on electron microscopy, suggesting possibilities of Alport’s syndrome. Ultrasonographic renal imaging yielded the presence of bilateral medullary nephrocalcinosis. Angiotensin converting enzyme inhibitors along with angiotensin receptor blockers were used to curb the disease progression. A final clinical exome sequencing corroborated the phenotype with a diagnosis of Alport’s syndrome type-1 linked to a novel pathogenic variant c.1892dup (p.Gly632ArgfsTer2) showing hemizygous single base pair insertion/duplication in COL4A5 gene. To the best of our knowledge, this unusual association of Alport’s syndrome with medullary nephrocalcinosis has not been reported worldwide in any previous medical literature making this report a primi one.
References
Tryggvason K, Zhou J, Hostikka SL, Shows TB. Molecular genetics of Alport syndrome. Kidney Int. 1993;43(1):38-44.
Miner JH. Pathology vs. molecular genetics:(re) defining the spectrum of Alport syndrome. Kidney Int. 2014;86(6):1081-3.
Colville DJ, Savige J. Alport syndrome. A review of the ocular manifestations. Ophthalmic Genet. 1997;18:161-73.
Gibson J, Fieldhouse R, Chan MM, Sadeghi-Alavijeh O, Burnett L, Izzi V, et al. Prevalence estimates of predicted pathogenic COL4A3–COL4A5 variants in a population sequencing database and their implications for Alport syndrome. J Am Soc Nephrol. 2021;32(9):2273-90.
Kruegel J, Rubel D, Gross O. Alport syndrome—insights from basic and clinical research. Nature Rev Nephrol. 2013;9(3):170-8.
Kugelman A, Grief Y, Gerhoni-Baruch R, Berkowitz D, Best LA, Guralnik L, Bentur L. Pulmonary presentation of esophagealleiomyomatosis associated with Alport syndrome in childhood. Isr Med Assoc J. 2003;5(4):293-4.
Schepens D, Verswijvel G, Kuypers D, Vanrenterghem Y. Renal cortical nephrocalcinosis. Nephrology Dialysis Transplantation. 2000 Jul 1;15(7):1080-2.
WHO. What is nephrocalcinosis?, 2019. Available at: https://healthjade.net/nephrocalcinosis/#googtte. Accessed on 10 November 2023.
Gross O, Licht C, Anders HJ, Hoppe B, Beck B, Tönshoff B, et al. Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy. Kidney Int. 2012;81:494-501.
Kashtan CE, Ding J, Gregory M, Gross O, Heidet L, Knebelmann B, Rheault M, Licht C. Clinical practice recommendations for the treatment of Alport syndrome: a statement of the Alport Syndrome Research Collaborative. Pediatric Nephrol. 2013;28:5-11.
